Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications (2022)
- Authors:
- USP affiliated authors: CUNHA, FERNANDO DE QUEIROZ - FMRP ; WANDERLEY, CARLOS WAGNER DE SOUZA - FMRP
- Unidade: FMRP
- DOI: 10.3389/fimmu.2022.816642
- Subjects: REPARAÇÃO DE DNA; IMUNOTERAPIA; NEOPLASIAS; FARMACOTERAPIA
- Keywords: DNA damage; PARP (poly(ADP-ribose); Cancer; Immune response; Immunotherapy; Polymerase
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Frontiers in Immunology
- ISSN: 1664-3224
- Volume/Número/Paginação/Ano: v. 13, art. 816642, p.1-10, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
WANDERLEY, Carlos Wagner de Souza et al. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, v. 13, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.816642. Acesso em: 28 dez. 2025. -
APA
Wanderley, C. W. de S., Correa, T. S., Scaranti, M., Cunha, F. de Q., & Barroso-Sousa, R. (2022). Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Frontiers in Immunology, 13, 1-10. doi:10.3389/fimmu.2022.816642 -
NLM
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2025 dez. 28 ] Available from: https://doi.org/10.3389/fimmu.2022.816642 -
Vancouver
Wanderley CW de S, Correa TS, Scaranti M, Cunha F de Q, Barroso-Sousa R. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications [Internet]. Frontiers in Immunology. 2022 ; 13 1-10.[citado 2025 dez. 28 ] Available from: https://doi.org/10.3389/fimmu.2022.816642 - Neuraminidase inhibitors rewire neutrophil function in vivo in murine sepsis and ex vivo in COVID-19
- Glycolytic tumor burden on pretreatment 18F-FDG PET/CT correlates with response and survival in metastatic NSCLC undergoing immune checkpoint inhibitors
- Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
- Platelets fuel the inflammasome activation of innate immune cells
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo
- Baseline glycolytic tumor burden predicts response and survival in NSCLC and melanoma patients treated with immune checkpoint inhibitors
- Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
- Controle da migracao de neutrofilos por fatores liberados de macrofagos estimulados com endotoxina de escherichia coli
- Edema de pata em cobaias: modelo para estudos da reacao inflamatoria de origem imunologica
- Comparison of five methods for the determination of lethal dose in acute toxicity studies
Informações sobre o DOI: 10.3389/fimmu.2022.816642 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003153421.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
